stockrowRelay Therapeutics, Inc.
RLAY Healthcare Biotechnology
Relay Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $15.4 million, up 53.4% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- 0.00%
- Free cash flow
- +2.13%
Quarter to June 2026, against a year earlier
Follow RLAY
Alert me
Relay Therapeutics, Inc. (RLAY) Total debt
Relay Therapeutics, Inc.'s total debt at the end of fiscal 2022 was $57.0M, up 147.8% from $23.0M in fiscal 2021. At the end of the quarter to 30 September 2023 it was $55.0M. Over the past ten years it has ranged from $0.00 (fiscal 2018) to $57.0M (fiscal 2022) — the current reading is the highest in ten years. Relay Therapeutics, Inc. ranks 126th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $57.0M | 147.83% |
| FY2021 | $23.0M | (8.00%) |
| FY2020 | $25.0M | 0.00% |
| FY2019 | $25.0M | — |
| FY2018 | $0.00 | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $55.0M | (1.79%) |
| Jun 2023 | $56.0M | 0.00% |
| Mar 2023 | $56.0M | (1.75%) |
| Dec 2022 | $57.0M | (6.56%) |
| 11 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| ABCL AbCellera Biologics Inc. compare | $81.0M |
| IRON Disc Medicine, Inc. compare | $59.3M |
| RLAY Relay Therapeutics, Inc. | $55.0M |
| ACAD ACADIA Pharmaceuticals Inc. compare | $48.1M |
| TNGX Tango Therapeutics, Inc. compare | $39.5M |
| XENE Xenon Pharmaceuticals Inc. compare | $11.0M |
| PBLS Parabilis Medicines, Inc. compare | $6.8M |
| EWTX Edgewise Therapeutics, Inc. compare | $5.6M |
| IOVA Iovance Biotherapeutics, Inc. compare | $1.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on RLAY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement